However, even among patients with favorable-risk features such as core-binding factor (CBF) or NPM1 + /FLT3-ITD- mutated AML who are able to tolerate and undergo intensive chemotherapy, older patients have worse outcomes compared with younger patients with these same genetic characteristics [15–17]. The gene discussed is FLT3; the disease is acute myeloid leukemia.